• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Bioventus Inc.

    8/14/25 4:31:57 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care
    Get the next $BVS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    BIOVENTUS INC.

    (Name of Issuer)


    Class A Common Stock, $0.001 par value per share

    (Title of Class of Securities)


    09075A108

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    09075A108


    1Names of Reporting Persons

    Nantahala Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,280,842.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,280,842.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,280,842.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.96 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    09075A108


    1Names of Reporting Persons

    Wilmot B. Harkey
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,280,842.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,280,842.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,280,842.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.96 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    09075A108


    1Names of Reporting Persons

    Daniel Mack
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,280,842.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,280,842.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,280,842.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.96 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    BIOVENTUS INC.
    (b)Address of issuer's principal executive offices:

    4721 EMPEROR BOULEVARD, SUITE 100 DURHAM, NORTH CAROLINA, 27703
    Item 2. 
    (a)Name of person filing:

    (1) Nantahala Capital Management, LLC ("Nantahala") (2) Wilmot B. Harkey (3) Daniel Mack (together the "Reporting Persons")
    (b)Address or principal business office or, if none, residence:

    130 Main St. 2nd Floor, New Canaan, Connecticut 06840
    (c)Citizenship:

    (1) Nantahala is a Massachusetts limited liability company. (2) Each of Messrs. Harkey and Mack is a citizen of the United States of America.
    (d)Title of class of securities:

    Class A Common Stock, $0.001 par value per share
    (e)CUSIP No.:

    09075A108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of June 30, 2025, Nantahala may be deemed to be the beneficial owner of 5,280,842 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares.
    (b)Percent of class:

    As of June 30, 2025, each of the Reporting Persons may be deemed to be the beneficial owner of the following percentage of the total number of Shares outstanding: (1) Nantahala Capital Management, LLC ("Nantahala") : 7.96% (2) Wilmot B. Harkey: 7.96% (3) Daniel Mack: 7.96%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.

     (ii) Shared power to vote or to direct the vote:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 5,280,842 Shares. (2) Wilmot B. Harkey: 5,280,842 Shares. (3) Daniel Mack: 5,280,842 Shares.

     (iii) Sole power to dispose or to direct the disposition of:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.

     (iv) Shared power to dispose or to direct the disposition of:

    (1) Nantahala Capital Management, LLC ("Nantahala") : 5,280,842 Shares. (2) Wilmot B. Harkey: 5,280,842 Shares. (3) Daniel Mack: 5,280,842 Shares.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in ss. 240.13d-1(b)(1)(ii)(E). See Item 4(a).
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Nantahala Capital Management, LLC
     
    Signature:/s/ Taki Vasilakis
    Name/Title:Taki Vasilakis / Chief Compliance Officer
    Date:08/14/2025
     
    Wilmot B. Harkey
     
    Signature:/s/ Wilmot B. Harkey
    Name/Title:Wilmot B. Harkey
    Date:08/14/2025
     
    Daniel Mack
     
    Signature:/s/ Daniel Mack
    Name/Title:Daniel Mack
    Date:08/14/2025
    Get the next $BVS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BVS

    DatePrice TargetRatingAnalyst
    7/7/2025$12.00Overweight
    Cantor Fitzgerald
    12/17/2024$12.00 → $13.00Underweight → Neutral
    Analyst
    12/7/2023$7.00Hold → Buy
    Canaccord Genuity
    8/9/2023$4.00 → $6.00Hold → Buy
    Craig Hallum
    11/22/2022Buy → Hold
    Craig Hallum
    11/9/2022$18.00 → $6.00Buy → Hold
    Canaccord Genuity
    11/9/2022Overweight → Underweight
    JP Morgan
    3/15/2022$30.00Buy
    Craig Hallum
    More analyst ratings

    $BVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference

    DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity Global Growth Conference on Tuesday, August 12, 2025, at 2:00 p.m. ET. A live webcast of the presentation, followed by a question-and-answer session will be available on the "Investors" section of the Company's website at www.bioventus.com and will be available for replay on that site following the event. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and

    8/7/25 4:15:00 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity

    DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has entered into a $400 million Senior Secured Credit Agreement (the "Credit Agreement") consisting of a $300 million term loan facility and a $100 million revolving credit facility on July 31, 2025. The new Credit Agreement will mature on July 31, 2030. Among the many enhancements, the new Credit Agreement provides for additional liquidity through an increase in the revolving credit facility from $40 million under the Company's previous credit facilities under the Credit and Guaranty Agreement, dated Decembe

    8/4/25 8:00:00 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products

    DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Administration (FDA) 510(k) clearances for both TalisMann™ and StimTrial™, expanding the Company's innovative portfolio of Peripheral Nerve Stimulation (PNS) solutions for chronic pain management. These two clearances mark an important step forward for Bioventus and represent a substantial growth opportunity as the Company looks to expand in the PNS market, which is currently estimated to be growing above 20 percent annually and expected to exceed $500 million by 2029. With TalisMann™ and StimT

    7/30/25 7:30:00 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $BVS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Bioventus Inc.

    SCHEDULE 13G/A - Bioventus Inc. (0001665988) (Subject)

    8/14/25 4:31:57 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Bioventus Inc.

    10-Q - Bioventus Inc. (0001665988) (Filer)

    8/6/25 7:45:10 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Bioventus Inc. (0001665988) (Filer)

    8/6/25 7:42:43 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $BVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bartholdson John A. bought $901,702 worth of shares (105,500 units at $8.55) (SEC Form 4)

    4 - Bioventus Inc. (0001665988) (Issuer)

    8/20/24 6:16:00 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $BVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bartholdson John A. converted options into 7,575 shares, increasing direct ownership by 11% to 79,620 units (SEC Form 4)

    4 - Bioventus Inc. (0001665988) (Issuer)

    6/10/25 5:49:16 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Director Bartholdson John A. converted options into 26,493 shares, increasing direct ownership by 58% to 72,045 units (SEC Form 4)

    4 - Bioventus Inc. (0001665988) (Issuer)

    6/5/25 9:22:27 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Director Sutter Martin P converted options into 26,493 shares, increasing direct ownership by 45% to 85,241 units (SEC Form 4)

    4 - Bioventus Inc. (0001665988) (Issuer)

    6/4/25 9:30:50 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $BVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Bioventus with a new price target

    Cantor Fitzgerald initiated coverage of Bioventus with a rating of Overweight and set a new price target of $12.00

    7/7/25 8:17:29 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus upgraded by Analyst with a new price target

    Analyst upgraded Bioventus from Underweight to Neutral and set a new price target of $13.00 from $12.00 previously

    12/17/24 7:32:13 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Bioventus from Hold to Buy and set a new price target of $7.00

    12/7/23 6:14:32 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $BVS
    Financials

    Live finance-specific insights

    View All

    Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025

    DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market opens on Wednesday, August 6, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-800-715-9871 and refer either to the Bioventus Inc. Conference Call or the conference ID 1859022. A live webcast of the call and accompanying materials will also be provided on the "Investo

    7/29/25 4:15:00 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

    DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's website

    4/28/25 8:00:00 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

    DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs

    2/28/25 7:30:00 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $BVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

    SC 13G/A - Bioventus Inc. (0001665988) (Subject)

    11/8/24 9:13:26 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

    SC 13G/A - Bioventus Inc. (0001665988) (Subject)

    7/15/24 5:15:58 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Bioventus Inc. (Amendment)

    SC 13G/A - Bioventus Inc. (0001665988) (Subject)

    2/14/24 4:51:41 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    $BVS
    Leadership Updates

    Live Leadership Updates

    View All

    Apyx Medical Corporation Announces Board Leadership Transition

    Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead

    5/9/24 7:00:00 AM ET
    $APYX
    $BVS
    $XTNT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Bioventus Appoints Mark Singleton as Chief Financial Officer

    DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has appointed Mark Singleton as the Company's Senior Vice President, Chief Financial Officer and Principal Accounting Officer, effective March 21, 2022. Mr. Singleton brings to Bioventus more than two decades of experience in operational finance and mergers & acquisitions at large and multi-national organizations. Most recently, he served as Vice President of Finance, Americas for Teleflex Incorporated, where he had financial responsibility for the $1.7 billion Americas business. Previous to this role, Mr. Si

    2/28/22 7:00:00 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care

    Bioventus Appoints Michelle McMurry-Heath to Board of Directors

    DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, has announced the appointment of Michelle McMurry-Heath, MD, PhD, to the Company's Board of Directors, effective January 1, 2022. Over the past 20 years, as both a physician and scientist, McMurry-Heath has served in dynamic policy, regulatory, commercial health care and advocacy roles. She will join the Board as an independent director. "We are thrilled Michelle will be joining the Bioventus Board of Directors," said Ken Reali, CEO. "Bioventus will leverage her background as a global medical innovation strategist as well as her ex

    12/21/21 9:25:00 AM ET
    $BVS
    Medical/Dental Instruments
    Health Care